GREENLAND MINES LTD Increase (Decrease) in Prepaid Expense
GREENLAND MINES LTD (GRML) reported Increase (Decrease) in Prepaid Expense of $2.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-08-17
- GREENLAND MINES LTD increase (decrease) in prepaid expense for the quarter ending 2026-06-30 was $1.93M.
- GREENLAND MINES LTD increase (decrease) in prepaid expense for the quarter ending 2026-03-31 was $749.95K, a 2600.27% increase year-over-year.
- GREENLAND MINES LTD increase (decrease) in prepaid expense for the quarter ending 2025-12-31 was $30.77K.
- GREENLAND MINES LTD increase (decrease) in prepaid expense for the quarter ending 2025-09-30 was $13.55K.
- GREENLAND MINES LTD increase (decrease) in prepaid expense for fiscal 2025 was $23.00K, a 74.51% decline from fiscal 2024.
- GREENLAND MINES LTD increase (decrease) in prepaid expense for fiscal 2024 was $90.23K, a 52056.07% increase from fiscal 2023.
- GREENLAND MINES LTD increase (decrease) in prepaid expense for fiscal 2023 was $173.00, a 99.83% decline from fiscal 2022.
- GREENLAND MINES LTD increase (decrease) in prepaid expense for fiscal 2022 was $99.20K.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 3 month as first filed | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 6 month as first filed | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 9 month as first filed | Increase (Decrease) in Prepaid Expense 12 month | Increase (Decrease) in Prepaid Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.93M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-17 | $2.68M 10-Q · filed 2026-08-17 | $2.71M derived: sum of 3 quarters · filed 2026-08-17 | $2.73M derived: sum of 4 quarters · filed 2026-08-17 | ||||
| 2026-03-31 | $749.95K 10-Q/A · filed 2026-08-14 | $780.72K derived: sum of 2 quarters · filed 2026-08-14 | $794.26K derived: sum of 3 quarters · filed 2026-08-14 | $745.17K derived: sum of 4 quarters · filed 2026-08-17 | ||||
| 2025-12-31 | $30.77K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | $44.32K derived: sum of 2 quarters · filed 2026-08-14 | -$4.77K derived: sum of 3 quarters · filed 2026-08-17 | $23.00K 10-K/A · filed 2026-08-14 | ||||
| 2025-09-30 | $13.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$35.54K derived: sum of 2 quarters · filed 2026-08-17 | -$7.77K 10-Q · filed 2025-11-13 | -$17.45K derived: sum of 4 quarters · filed 2026-08-17 | ||||
| 2025-06-30 | -$49.09K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-17 | -$21.32K 10-Q · filed 2026-08-17 | -$31.00K derived: sum of 3 quarters · filed 2026-08-17 | -$81.75K derived: sum of 4 quarters · filed 2026-08-17 | ||||
| 2025-03-31 | $27.77K 10-Q/A · filed 2026-08-14 | $18.09K derived: sum of 2 quarters · filed 2026-08-14 | -$32.66K derived: sum of 3 quarters · filed 2026-08-14 | $121.84K derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2024-12-31 | -$9.68K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | -$60.43K derived: sum of 2 quarters · filed 2026-08-14 | $94.07K derived: sum of 3 quarters · filed 2026-08-14 | $90.23K 10-K/A · filed 2026-08-14 | ||||
| 2024-09-30 | -$50.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $103.75K derived: sum of 2 quarters · filed 2025-11-13 | $99.91K 10-Q · filed 2025-11-13 | $98.47K derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $154.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $150.66K 10-Q · filed 2025-08-18 | $149.22K derived: sum of 3 quarters · filed 2025-08-18 | $153.58K derived: sum of 4 quarters · filed 2025-08-18 | ||||
| 2024-03-31 | -$3.84K 10-Q · filed 2025-05-15 | -$27.00K 10-Q · filed 2024-05-23 | -$5.28K derived: sum of 2 quarters · filed 2025-05-15 | -$917.00 derived: sum of 3 quarters · filed 2025-05-15 | -$126.54K derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | -$1.44K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.92K derived: sum of 2 quarters · filed 2025-03-31 | -$122.70K derived: sum of 3 quarters · filed 2025-03-31 | $173.00 10-K · filed 2025-03-31 | -$72.20K 10-K · filed 2024-04-17 | |||
| 2023-09-30 | $4.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-19 | -$121.26K derived: sum of 2 quarters · filed 2024-11-19 | $1.61K 10-Q · filed 2024-11-19 | -$41.72K 10-Q · filed 2023-11-17 | -$40.18K derived: sum of 4 quarters · filed 2024-11-19 | |||
| 2023-06-30 | -$125.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-19 | -$2.75K 10-Q · filed 2024-08-19 | $36.00K 10-Q · filed 2023-08-21 | -$44.54K derived: sum of 3 quarters · filed 2024-08-19 | -$121.73K derived: sum of 4 quarters · filed 2024-08-19 | |||
| 2023-03-31 | $122.88K 10-Q · filed 2024-05-23 | $81.09K derived: sum of 2 quarters · filed 2024-05-23 | $3.90K derived: sum of 3 quarters · filed 2024-05-23 | $192.87K derived: sum of 4 quarters · filed 2024-05-23 | ||||
| 2022-12-31 | -$41.79K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-17 | -$118.98K derived: sum of 2 quarters · filed 2024-04-17 | $70.00K derived: sum of 3 quarters · filed 2024-04-17 | $99.20K 10-K · filed 2024-04-17 | ||||
| 2022-09-30 | -$77.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | $111.78K derived: sum of 2 quarters · filed 2023-11-17 | $140.99K 10-Q · filed 2023-11-17 | |||||
| 2022-06-30 | $188.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $218.17K 10-Q · filed 2023-08-21 | ||||||
| 2022-03-31 | $29.20K 10-Q · filed 2023-05-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |